236 related articles for article (PubMed ID: 12692781)
21. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
[TBL] [Abstract][Full Text] [Related]
22. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
23. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
24. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2.
Ide H; Yoshida T; Matsumoto N; Aoki K; Osada Y; Sugimura T; Terada M
Cancer Res; 1997 Nov; 57(22):5022-7. PubMed ID: 9371496
[TBL] [Abstract][Full Text] [Related]
25. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31.
Moffatt KA; Johannes WU; Hedlund TE; Miller GJ
Cancer Res; 2001 Oct; 61(19):7122-9. PubMed ID: 11585744
[TBL] [Abstract][Full Text] [Related]
26. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
[TBL] [Abstract][Full Text] [Related]
27. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
28. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
29. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
30. The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer.
Chang GT; Jhamai M; van Weerden WM; Jenster G; Brinkmann AO
Endocr Relat Cancer; 2004 Dec; 11(4):815-22. PubMed ID: 15613454
[TBL] [Abstract][Full Text] [Related]
31. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs.
Schwartz GG; Oeler TA; Uskoković MR; Bahnson RR
Anticancer Res; 1994; 14(3A):1077-81. PubMed ID: 8074453
[TBL] [Abstract][Full Text] [Related]
32. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
33. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth.
Qiao S; Tuohimaa P
Biochem Biophys Res Commun; 2004 Jun; 319(2):358-68. PubMed ID: 15178414
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
35. Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells.
Thelen P; Peter T; Hünermund A; Kaulfuss S; Seidlová-Wuttke D; Wuttke W; Ringert RH; Seseke F
BJU Int; 2007 Jul; 100(1):199-203. PubMed ID: 17488304
[TBL] [Abstract][Full Text] [Related]
36. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
Church DR; Lee E; Thompson TA; Basu HS; Ripple MO; Ariazi EA; Wilding G
Prostate; 2005 May; 63(2):155-68. PubMed ID: 15486991
[TBL] [Abstract][Full Text] [Related]
37. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells.
Stewart LV; Weigel NL
Prostate; 2005 Jun; 64(1):9-19. PubMed ID: 15651061
[TBL] [Abstract][Full Text] [Related]
38. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
39. Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3.
Murthy S; Marcelli M; Weigel NL
Prostate; 2003 Sep; 56(4):293-304. PubMed ID: 12858358
[TBL] [Abstract][Full Text] [Related]
40. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
Bao BY; Hu YC; Ting HJ; Lee YF
Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
